Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma in Europe.
- DOI
- 10.1080/10428194.2026.2715822
- Published
- 2026 Nov 9
- Container
- Leukemia & lymphoma
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/10428194.2026.2715822,
title = {Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma in Europe.},
author = {Mitteldorf C and de Masson A and Beylot-Barry M and Gutierrez A and Muniesa C and Gonzalez Barca E and Dippel E and Wobser M and Zomas A and Stache V and Assaf C},
year = {2026},
journal = {Leukemia \& lymphoma},
doi = {10.1080/10428194.2026.2715822},
url = {https://doi.org/10.1080/10428194.2026.2715822}
}RIS
TY - JOUR TI - Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma in Europe. AU - Mitteldorf C AU - de Masson A AU - Beylot-Barry M AU - Gutierrez A AU - Muniesa C AU - Gonzalez Barca E AU - Dippel E AU - Wobser M AU - Zomas A AU - Stache V AU - Assaf C PY - 2026 JO - Leukemia & lymphoma DO - 10.1080/10428194.2026.2715822 UR - https://doi.org/10.1080/10428194.2026.2715822 ER -
APA
C, M., A, D. M., M, B., A, G., C, M., E, G. B., E, D., M, W., A, Z., V, S., & C, A. (2026). Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma in Europe.. Leukemia & lymphoma. https://doi.org/10.1080/10428194.2026.2715822
Source records
- pubmed · retrieved 2026-11-10T21:14:58.038Z